GlassScriptPhysician profile
Sara Atallah
NPI 1598170763
$2,101.52
in general payments reported to CMS, 2019-2025
14 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $154 · 2021: $35.82 · 2022: $16.27 · 2023: $139 · 2024: $268 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522 · Education: $22.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.47 |
| Education | $22.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $439.45 | 2020-2024 | Farxiga |
| Alexion Pharmaceuticals, INC. | $373.80 | 2019-2025 | Ultomiris |
| Travere Therapeutics, INC. | $304.39 | 2025 | Filspari, Thiola |
| Nxstage Medical, INC. | $236.02 | 2025 | Nxstage System One, Pureflow Sl |
| Ardelyx, INC. | $123.72 | 2024 | Xphozah 30 Mg |
| Bayer Healthcare Pharmaceuticals INC. | $120.62 | 2025 | |
| Novo Nordisk INC | $116.45 | 2025 | Rivfloza, Wegovy |
| Akebia Therapeutics INC | $99.10 | 2025 | Vafseo |
| Novartis Pharmaceuticals Corporation | $72.51 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $59.11 | 2020-2025 | Jynarque |
| Amgen INC. | $56.58 | 2022-2025 | Krystexxa |
| Aurinia Pharma U.S., INC. | $44.20 | 2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $35.02 | 2023-2025 | Tarpeyo |
| Scpharmaceuticals INC. | $20.55 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Atallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.